Clinical trials: NSCLC (non-small Cell Lung Cancer)
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Metastatic Non Small Cell Lung Cancer
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM…
- Trial name
- OUTRUN (NCT03497767)
- Testing
- Osimertinib, Stereotactic Radiosurgery (SRS)
- Where
- 13 sites in Australia, Singapore
- Volunteers
- 40 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Advanced/Metastatic NSCLC
Impact of Circadian Rhythm on Immunotherapy
This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population.
- Trial name
- NCT07224971
- Testing
- Immunotherapy - PD-1 Blocker
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Liza Villaruz, MD
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel
The study compares two combinations of chemotherapy in patients with advanced or metastatic NSCLC: 50% of the patients are treated with cisplatin and docetaxel, the other 50% with oxaliplatin and docetaxel.
- Trial name
- Taxelox (NCT01222312)
- Testing
- Cisplatin, Oxaliplatin, Docetaxel
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Krankenhaus Nordwest
Brain Cancer, Neoplasm Metastasis
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4…
- Conditions
- Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00946673
- Testing
- Vorinostat, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Non Small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer
- Trial name
- NCT03195569
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who…
- Trial name
- NCT06542731
- Testing
- ONO-4578, ONO-4538, Docetaxel
- Where
- 13 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy.
- Conditions
- Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Pleural Effusion, Malignant
- Trial name
- NCT04749602
- Testing
- Nivolumab
- Where
- 5 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Kidney Cancer Research Bureau
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC
The purpose of this study is to determine whether stereotactic radiosurgery combination with Anlotinib could improve the efficacy and outcomes for non-small cell lung cancer with limited brain metastases.
- Trial name
- AnloSBRT (NCT04912128)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Third Hospital
Metastatic Non-small Cell Lung Cancer
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
The purpose of this study is to test the safety of dacomitinib and osimertinib, at increasing doses, to find out what effects, if any, this combination of drugs has on people with metastatic EGFR mutant lung cancer that has not…
- Trial name
- NCT03810807
- Testing
- Dacomitinib, Osimertinib
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body (metastatic) on single agent…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06731270
- Testing
- Atezolizumab, Biospecimen Collection, Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Carcinoma, Non-small-cell Lung
Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer
The purpose of this study is to evaluate the interest of breath holding for the prevention of radiation pneumonitis following conformal radiation therapy.
- Trial name
- NCT00349102
- Testing
- Free breathing, Breath holding
- Where
- 7 sites in France
- Volunteers
- 242 people
- Sponsor
- Centre Leon Berard
Cancer
Imaging NSCLC Treatment Response to Immunotherapy
This feasibility study will aim to assess the potential for functional imaging biomarkers (18FDG PET-CT and DW-MRI) to differentiate immunotherapy induced inflammation, indicative of response from non-response in patients with…
- Trial name
- NCT02753569
- Testing
- Imaging - DW-MRI, FDG PET-CT
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Lung Cancer
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in treating patients…
- Trial name
- NCT00002656
- Testing
- pyrazoloacridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.